113 related articles for article (PubMed ID: 22702414)
1. Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT.
Chevallier P; Labopin M; Buchholz S; Ganser A; Ciceri F; Lioure B; Faul C; Guillerm G; Finke J; Huynh A; Schubert J; Kolb HJ; Polge E; Nagler A; Mohty M
Eur J Haematol; 2012 Sep; 89(3):214-9. PubMed ID: 22702414
[TBL] [Abstract][Full Text] [Related]
2. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT.
Chevallier P; Labopin M; Milpied N; Cornelissen JJ; Blaise D; Petersen E; Sandstedt A; Goker H; Socie G; Rocha V; Mohty M;
Bone Marrow Transplant; 2012 Nov; 47(11):1442-7. PubMed ID: 22504932
[TBL] [Abstract][Full Text] [Related]
3. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
Martin MG; Uy GL; Procknow E; Stockerl-Goldstein K; Cashen A; Westervelt P; Abboud CN; Augustin K; Luo J; DiPersio JF; Vij R
Bone Marrow Transplant; 2009 Jul; 44(1):13-7. PubMed ID: 19139740
[TBL] [Abstract][Full Text] [Related]
4. Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.
El-Jawahri A; Li S; Ballen KK; Cutler C; Dey BR; Driscoll J; Hunnewell C; Ho VT; McAfee SL; Poliquin C; Saylor M; Soiffer RJ; Spitzer TR; Alyea E; Chen YB
Biol Blood Marrow Transplant; 2016 Jan; 22(1):80-5. PubMed ID: 26260679
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia.
Tischer J; Stemmler HJ; Engel N; Hubmann M; Fritsch S; Prevalsek D; Schulz C; Zoellner AK; Bücklein V; Hill W; Ledderose G; Hausmann A
Ann Hematol; 2013 Oct; 92(10):1379-88. PubMed ID: 23928857
[TBL] [Abstract][Full Text] [Related]
6. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.
Farag SS; Wood LL; Schwartz JE; Srivastava S; Nelson RP; Robertson MJ; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Jones DR
Leukemia; 2011 Apr; 25(4):599-605. PubMed ID: 21252987
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
[TBL] [Abstract][Full Text] [Related]
9. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.
Kirschbaum MH; Stein AS; Popplewell L; Delioukina M; Chen R; Nakamura R; Snyder D; Conrad J; Lacey SF; Frankel P; Dagis A; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2012 Mar; 18(3):432-40. PubMed ID: 21801703
[TBL] [Abstract][Full Text] [Related]
10. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
Shimoni A; Shem-Tov N; Volchek Y; Danylesko I; Yerushalmi R; Nagler A
Bone Marrow Transplant; 2012 Oct; 47(10):1274-82. PubMed ID: 22327135
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
Martins C; Lacerda JF; Lourenço F; Carmo JA; Lacerda JM
Acta Med Port; 2005; 18(5):329-37. PubMed ID: 16611537
[TBL] [Abstract][Full Text] [Related]
12. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
13. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886
[TBL] [Abstract][Full Text] [Related]
14. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation.
Gorin NC; Labopin M; Boiron JM; Theorin N; Littlewood T; Slavin S; Greinix H; Cahn JY; Alessandrino EP; Rambaldi A; Nagler A; Polge E; Rocha V;
J Clin Oncol; 2006 Aug; 24(24):3959-66. PubMed ID: 16880451
[TBL] [Abstract][Full Text] [Related]
15. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
[TBL] [Abstract][Full Text] [Related]
16. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.
Blaise DP; Michel Boiron J; Faucher C; Mohty M; Bay JO; Bardoux VJ; Perreau V; Coso D; Pigneux A; Vey N
Cancer; 2005 Nov; 104(9):1931-8. PubMed ID: 16178004
[TBL] [Abstract][Full Text] [Related]
17. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.
Magenau J; Westervelt P; Khaled S; McGuirk J; Hari P; Eapen M; Becker PS; Parkin B; Braun T; Logan B; Wang H; Jagasia M; Rowley SD; Kim DD; Schechter T; Frey N; Scott B; Churay T; Lieland S; Forman S; Mineishi S
Bone Marrow Transplant; 2017 Jan; 52(1):59-65. PubMed ID: 27427921
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
19. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison.
Mohty M; de Lavallade H; Ladaique P; Faucher C; Vey N; Coso D; Stoppa AM; Gastaut JA; Blaise D
Leukemia; 2005 Jun; 19(6):916-20. PubMed ID: 15843817
[TBL] [Abstract][Full Text] [Related]
20. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Kebriaei P; Basset R; Ledesma C; Ciurea S; Parmar S; Shpall EJ; Hosing C; Khouri I; Qazilbash M; Popat U; Alousi A; Nieto Y; Jones RB; de Lima M; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1819-26. PubMed ID: 22750645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
